通过调解巨细胞泡细胞形成,SPA促进动脉样硬化-简要报告
Skylar D King1, Dunpeng Cai1, Alisha Pillay2
1Department of Surgery (S.D.K., D.C., M.M.F., S.-Y.C.), University of Missouri School of Medicine, Columbia.
Arteriosclerosis, thrombosis, and vascular biology
|October 3, 2024
概括
表面活性蛋白A (SPA) 通过增加巨细胞泡细胞的形成和CD36表达来促进动脉样硬化. 在小鼠中,SPA缺乏减轻动脉样硬化,减少泡细胞的积累.
科学领域:
- 心血管研究研究心血管研究
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 动脉样硬化是一种炎症性疾病,其中巨细胞泡细胞是关键.
- 表面活性蛋白A (SPA) 调节炎症中的巨细胞功能.
- 在动脉样硬化和泡细胞形成中SPA的作用是未知的.
研究的目的:
- 为了研究SPA在动脉样硬化中的作用.
- 为了确定SPA对巨细胞泡细胞形成的影响.
主要方法:
- 在人类和小鼠动脉样硬化动脉中评估SPA表达.
- 使用了野生类型和SPA缺乏的小鼠,食高脂肪饮食.
- 用巨细胞进行了体外研究,以评估泡细胞的形成.
主要成果:
- 在动脉样硬化病变中,SPA表达升高.
- 缺少SPA可以减少高胆固醇血症,动脉样硬化和泡细胞数量.
- 缺少SPA降低了细胞内胆固醇和泡细胞的形成,降低了CD36.
- 在人类巨细胞中,SPA增加了CD36表达.
结论:
- SPA是一种促进动脉样硬化的新型因素.
- 通过增加拾尸体受体CD36的表达,SPA增强了泡细胞的形成和动脉样硬化.
- 这导致细胞氧化低密度脂蛋白 (OxLDL) 的吸收增加.
更多相关视频
09:41Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
Published on: October 18, 2017
13.4K
07:36Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
Published on: September 27, 2018
10.1K
相关概念视频
Inflammation
46.6K
Overview
46.6K
Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Peripheral Artery Disease I: Introduction
659
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
659
